A$0.036 CDX.AX CardieX ASX Market Closed 21 Jan 2026: Oversold bounce
CardieX Limited (CDX.AX) closed at A$0.036 on the ASX on 21 Jan 2026, creating an oversold bounce setup for short-term traders. CDX.AX stock trades below its 50-day average of A$0.032 and far below its 200-day average of A$0.065. Volume was 176,535 shares, below the 30-day average volume of 458,209. The company’s YTD move of -63.64% signals heavy selling, but low float and recent volume spikes can fuel a technical rebound. We examine catalysts, valuation, and a tight trading plan for an oversold bounce.
Price snapshot and short-term setup for CDX.AX stock
CardieX (CDX.AX) closed A$0.036 on the ASX with a day low of A$0.035 and a day high of A$0.038. Volume finished at 176,535 shares, below the average of 458,209. The stock sits near its year low of A$0.027 and far from the year high of A$0.175. These facts set a classic oversold profile where a short-term bounce is possible if demand returns.
Why an oversold bounce is plausible for CDX.AX stock
Momentum indicators show stretched weakness and price below both the 50-day and 200-day averages, supporting a mean-reversion trade. The health-care sector on the ASX has mixed returns, but small-cap medical devices stocks often snap back on trial news or contract updates. Low relative volume and a compressed price can produce sharp short squeezes in CDX.AX stock if a positive trigger appears.
Fundamentals, valuation and Meyka AI grade for CDX.AX stock
CardieX operates in medical devices and remote monitoring with FY metrics showing revenue per share of A$0.015 and EPS of -A$0.04. Price-to-sales is 3.15 and price-to-book is 2.65. Current ratio is 1.56 and debt-to-equity is 0.66, indicating manageable balance-sheet leverage.
Meyka AI rates CDX.AX with a score out of 100: 59.71 (C+) – HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, forecasts, and analyst consensus. These grades are informational and not advice.
Risks and catalysts that could move CDX.AX stock
Key risks include continued negative earnings, thin liquidity, and limited analyst coverage. CardieX shows negative operating cash flow per share of -A$0.026 and an interest coverage ratio sharply negative, which raises funding risk. Catalysts that could prompt a bounce include ASX announcements, trial contract wins, or renewed commercial uptake of SphygmoCor devices. News flow typically produces outsized moves in low-cap ASX healthcare names.
Price targets, forecast and technical trade levels for CDX.AX stock
Analyst consensus is not available, so we use technical levels for short-term targets. A conservative bounce target is A$0.060; an extended recovery target is A$0.120. Those imply upside of 66.67% and 233.33% from A$0.036 respectively. Meyka AI’s forecast model projects a 12-month value of A$0.02288 versus the current A$0.036, implying model-based downside of -36.46%. Forecasts are model-based projections and not guarantees.
Trading strategy for an oversold bounce in CDX.AX stock
For traders, consider a micro-sized position given thin liquidity and volatility. Enter near A$0.034–A$0.038 on confirmed demand and set a tight stop-loss at A$0.028 to limit downside. Take partial profits at A$0.060 and reassess at A$0.120. Monitor ASX announcements, volume spikes, and sector updates for entry and exit signals. Use position sizing to limit portfolio risk to 1–2% per trade.
Final Thoughts
CDX.AX stock closed at A$0.036 on 21 Jan 2026 and fits the oversold bounce profile for short-term traders. Technical factors—price below the 50-day and 200-day averages, low volume versus average, and a year-to-date decline of -63.64%—create a setup where a news-driven rebound could be sharp. Fundamentals remain weak with EPS -A$0.04, negative operating cash flow per share -A$0.026, and limited analyst coverage, so speculative trades should be small and disciplined. Meyka AI’s forecast model projects A$0.02288, implying -36.46% versus the current price; that underlines model caution. For active traders we outline a short-term technical target of A$0.060 with a stop at A$0.028. Investors seeking longer-term exposure should wait for improving cash flow or confirmed commercial contracts. For live alerts and realtime context see CardieX (CDX.AX) on Meyka AI and monitoring of ASX news Market announcement summary and market commentary Investing.com ETF/CDX summary. Forecasts are model-based projections and not guarantees.
FAQs
Is CDX.AX stock a buy after the recent drop?
CDX.AX stock looks oversold but fundamentals are weak. Traders may buy small positions for a technical bounce. Long-term investors should wait for cash flow improvement or clear commercial wins. This is not financial advice.
What is Meyka AI’s forecast for CDX.AX stock?
Meyka AI’s forecast model projects A$0.02288 for CDX.AX stock over 12 months, implying a model-based downside of about -36.46% from A$0.036. Forecasts are model-based projections and not guarantees.
What short-term price target should traders use for CDX.AX stock?
For an oversold bounce, a short-term technical target is A$0.060, with a tighter stop at A$0.028. Use small position sizes due to thin liquidity and headline-driven moves.
How does CardieX’s balance sheet affect CDX.AX stock risk?
CardieX has a current ratio of 1.56 and debt-to-equity of 0.66, but operating cash flow per share is negative at -A$0.026. That increases funding risk and means stock moves can be volatile on financing news.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
